Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | Camrelizumab + Rivoceranib |
Indication/Tumor Type | hepatocellular carcinoma |
Response Type | not predictive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | hepatocellular carcinoma | not predictive | Camrelizumab + Rivoceranib | Clinical Study - Cohort | Actionable | In a Phase II trial (RESCUE), combined Camrelizumab (SHR-1210) and Rivoceranib (apatinib) treatment in patients with CD274 (PD-L1)-positive (TPS>=1%) advanced hepatocellular carcinoma demonstrated a similar objective response rate (31.8%, 7/22 vs. 18.8%, 6/32) and progression-free survival event rate (63.6%,14/22 vs. 75.0%, 24/32) compared to patients with CD274 (PD-L1)-negative (TPS<1%) tumors (PMID: 33087333; NCT03463876). | 33087333 |
PubMed Id | Reference Title | Details |
---|---|---|
(33087333) | Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial. | Full reference... |